围手术期继续阿司匹林对腹腔镜结直肠癌手术出血并发症的影响:倾向性评分匹配分析
本研究回顾性分析789例腹腔镜结直肠癌手术患者,经倾向性评分匹配后比较围手术期继续阿司匹林单药治疗(cAPT组,105例)与非继续组(non-cAPT组,105例)的出血并发症。结果显示两组出血并发症发生率无显著差异(2.9% vs 1.0%,p=0.317),但cAPT组出血多发生在重新启用其他抗血栓药物后(中位POD 7),提示继续阿司匹林单药可能安全,但重启其他抗血栓药物需谨慎。
要点
- 围手术期继续阿司匹林单药不增加腹腔镜结直肠癌手术出血并发症风险。
- cAPT组出血多发生于重新启用其他抗血栓药物后(中位POD 7)。
- non-cAPT组出血均为吻合口出血,多发生于术后早期(中位POD 1)。
核心结论
- 对于接受抗血小板治疗的患者,腹腔镜结直肠癌手术围手术期继续阿司匹林单药治疗可能是安全的。
- 当使用多种抗血栓药物时,重新启用其他抗血栓药物需谨慎考虑。
研究设计与样本
- 回顾性分析,采用倾向性评分匹配(PSM)。
- 共789例患者符合纳入标准,分为继续阿司匹林单药治疗组(cAPT,n=140,围手术期继续治疗且停药不超过2天)和非cAPT组(n=649,停药超过3天或未接受抗血小板治疗)。
- 经1:1 PSM后,每组各提取105例患者。
- 围手术期抗血小板管理基于机构委员会批准的抗血栓管理指南。
主要发现
- PSM队列中,两组患者人口学特征均衡。
- 术中结局:手术时间(p=0.969)、失血量(p=0.068)和输血(p=0.517)无显著差异。
- 术后总体并发症发生率:cAPT组20.0%,non-cAPT组13.3%(p=0.195)。
- 出血并发症发生率:cAPT组2.9%,non-cAPT组1.0%(p=0.317),无显著差异。
- 全队列14例出血并发症中,non-cAPT组7例均为吻合口出血,多发生于术后早期(中位POD 1);cAPT组7例均接受了阿司匹林以外的其他抗血栓药物,出血部位多样且发生较晚(中位POD 7),多在重新启用其他抗血栓药物后。
临床怎么用
- 对于接受抗血小板治疗的腹腔镜结直肠癌手术患者,可考虑围手术期继续阿司匹林单药治疗,但需基于机构指南个体化决策。
- 对于使用多种抗血栓药物的患者,重新启用其他抗血栓药物时应密切监测出血风险。
局限性
- 回顾性研究设计,存在选择偏倚可能。
- 样本量有限,出血并发症事件数较少。
- 单中心研究,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In laparoscopic surgery for colorectal cancer (CRC) for patients who receive antiplatelet therapy (APT), it remains unclear whether APT should be continued or temporarily withdrawn. We investigated the safety of perioperative aspirin continuation, specifically focused on bleeding complications. METHODS: We performed retrospective analysis utilizing propensity score-matching (PSM). In total, 789 patients satisfied the inclusion criteria, and were divided into two groups. Patients in the continued aspirin monotherapy (cAPT) group continued treatment perioperatively with not more than 2 days of withdrawal (n = 140). Patients with more than 3 days withdrawal of aspirin or who did not receive APT at all were assigned to the non-cAPT group (n = 649). After 1:1 PSM, 105 patients were extracted from each group. Perioperative APT management was determined based on our institutional committee-approved guidelines for antithrombotic management. RESULTS: In PSM cohorts, all patient demographics were comparable between the groups. Regarding intraoperative outcomes, we found no significant difference in operation duration (p = 0.969), blood loss (p = 0.068), and blood transfusion (p = 0.517). Postoperative overall morbidity was 20.0% and 13.3% in the cAPT and non-cAPT groups, respectively (p = 0.195). The incidence of bleeding complications was also comparable between the groups (2.9% vs. 1.0%, p = 0.317). Assessing the 14 cases with bleeding complications overall in the full cohort, all 7 cases in the non-cAPT group had anastomotic bleeding, which was generally observed shortly after surgery [median postoperative day (POD) 1]. All 7 cases in the cAPT group received additional antithrombotics other than aspirin; bleeding occurred at various sites relatively later (median POD 7), mostly after reinstitution of additional antithrombotic agents. CONCLUSIONS: For patients receiving APT, perioperative continuation of aspirin monotherapy could be safe in laparoscopic CRC surgery; however, careful consideration is required at reinstitution of additional antithrombotics where multiple antithrombotic agents are used.
引用
- Takahashi R, Fujikawa T. Impact of perioperative aspirin continuation on bleeding complications in laparoscopic colorectal cancer surgery: a propensity score-matched analysis. Surg Endosc. 2020. PMID: 32372221. doi:10.1007/s00464-020-07604-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。